STOCK TITAN

Q32 Bio Inc. (QTTB) corrects director grant to 10,826 stock options

(Neutral)
(Neutral)
Form Type
4/A

Rhea-AI Filing Summary

Q32 Bio Inc. director Sven Ante Lundberg reported a grant of 10,826 stock options on June 12, 2026 at an exercise price of $12.64 per share, expiring June 11, 2036. The options vest in full upon the earlier of June 12, 2027 or the next annual stockholders’ meeting, and this Form 4/A corrects the number of options originally reported.

Positive

  • None.

Negative

  • None.
Insider Lundberg Sven Ante
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1, F2 10,826 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 10,826 shares (Direct)
Footnotes (2)
  1. F1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
  2. F2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Stock options granted 10,826 options Grant to director Sven Ante Lundberg on 2026-06-12
Exercise price $12.6400 per share Exercise price for the granted stock options
Expiration date 2036-06-11 Expiration of the granted stock options
Underlying common shares 10,826 shares Common stock underlying the stock option grant
Post-transaction option holdings 10,826 options Total directly held options of this grant after the transaction
Vesting reference date June 12, 2027 Latest date when options vest, or earlier at next annual meeting
Stock Option (Right to Buy) financial
"The security title is listed as "Stock Option (Right to Buy)" for this grant."
exercise price financial
"The options carry an exercise price of $12.6400 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares underlying this option shall vest and become exercisable in full."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"The option’s expiration date is reported as 2036-06-11."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Q32 Bio Inc. (QTTB) disclose in this Form 4/A?

Q32 Bio Inc. reported that director Sven Ante Lundberg received a grant of 10,826 stock options on June 12, 2026. These options are exercisable at $12.64 per share and represent a new derivative position reported as directly owned.

How many stock options were granted to Sven Ante Lundberg at Q32 Bio Inc. (QTTB)?

Sven Ante Lundberg was granted 10,826 stock options in Q32 Bio Inc. common stock. Following this grant, he held 10,826 of these options, all reported as directly owned in the amended Form 4 filing.

What is the exercise price and expiration date of the Q32 Bio (QTTB) options granted?

The granted options carry an exercise price of $12.64 per share and expire on June 11, 2036. These terms define the cost to acquire common shares and the final date by which the options must be exercised.

When do Sven Ante Lundberg’s Q32 Bio (QTTB) stock options vest?

The options vest and become fully exercisable upon the earlier of June 12, 2027 or Q32 Bio’s next annual stockholders’ meeting. Vesting is subject to his continued service on the vesting date, as specified in the footnotes.

Why was this Q32 Bio Inc. (QTTB) Form 4 amended?

The Form 4/A states it was filed solely to correct the number of options awarded to Sven Ante Lundberg on June 12, 2026. The amendment clarifies the accurate grant size of 10,826 options tied to Q32 Bio common stock.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lundberg Sven Ante

(Last)(First)(Middle)
Q32 BIO INC.
830 WINTER STREET

(Street)
WALTHAM MASSACHUSETTS 02451

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)
06/16/2026
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$12.6406/12/2026A10,826(1) (2)06/11/2036Common Stock10,826(1)$010,826(1)D
Explanation of Responses:
1. This Form 4 amendment is being filed solely to amend the Form 4 filed on June 16, 2026 to correct the number of options awarded to the Reporting Person on June 12, 2026.
2. The shares underlying this option shall vest and become exercisable in full upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
/s/ Eric Bell, Attorney-in-Fact07/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)